[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ercp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ercp":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,49,79,99,124,154,177,203,235,266,283,306],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053368","effect-of-patient-anxiety-level-prior-to-undergoing-ercp-and-procedure-tolerability-and-outcomes-100053368",false,"NCT07699731","Effect of Patient Anxiety Level Prior to Undergoing ERCP and Procedure Tolerability and Outcomes.","The Effect of Pre-procedural Anxiety Level on Procedure Tolerability and Quality of ERCP in Consciously Sedated Patients","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Undergoing ERCP for any indication with conscious sedation\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Inability or refusal to provide informed consent\n* Cognitive impairment or language barriers precluding questionnaire completion\n* Emergent ERCP where pre-procedural questionnaire administration is not feasible","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Endoscopic Retrograde Cholangiopancreatography (ERCP) is a specialized procedure combining upper GI endoscopy and x-rays to treat hepatopancreaticobiliary diseases. Patient experiences after ERCP has been relatively understudied.\n\nThe goal of this prospective observational study is to understand how anxiety before ERCP affects patient experience and tolerance of the procedure.\n\nThis study includes adults (18 years and older) undergoing ERCP with conscious sedation at Kingston Health Sciences Centre. Researchers will measure pre-procedure anxiety and examine how it relates to patient comfort, cooperation during the procedure, and overall patient-reported experience.\n\nThe main questions are whether higher pre-procedure anxiety is associated with lower procedure tolerability and reduced cooperation during ERCP.\n\nParticipants will:\n\n1. Complete a short anxiety questionnaire before the procedure\n2. Undergo ERCP with standard sedation as planned by their care team\n3. Complete a post-procedure questionnaire about comfort, pain, and other symptoms\n4. Have procedure details and outcomes recorded from medical records\n\nEndoscopists will also complete a short survey to state any concerns prior to procedure as well as evaluate patient's cooperation during the procedure.\n\nPatient-reported experience will be compared with physician assessments of cooperation during the procedure.\n\nFindings may help recognize patients at higher risk of distress during ERCP and guide strategies to improve comfort, sedation planning, and overall procedure quality to lead to the best outcomes.",[24,25,26],"Anxiety","Biliary and Pancreatic Diseases","ERCP",[26,28,29,30,31,32,33,34,35],"Endoscopic retrograde cholangiopancreatography","Conscious sedation","Pre-procedural anxiety","Patient experience","STAI-Y","PRO-STEP","Upper endoscopy","Procedural sedation","NOT_YET_RECRUITING","2026-07-09",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":20},"2026-08-01",{"date":44,"type":20},"2027-10-01",{"name":46,"class":47},"Mandip Rai","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100598434","indomethacin-vs-diclofenac-for-preventing-pep-100598434","NCT07071441","Indomethacin vs Diclofenac for Preventing PEP","Rectal Indomethacin Versus Diclofenac for Prevention of Post-ERCP Panceratitis (IDPPP2): A Multicenter, Double-blind, Randomized, Control Trial","Inclusion Criteria:\n\n* 18-90 years old patients with native papilla who planned to undergo ERCP\n\nExclusion Criteria:\n\n* Previous biliary sphincterotomy and papillary large balloon dilation\n* Planned for placements of pancreatic duct stents (eg. pancreatic duct strictures, planned ampullectomy)\n* Allergy to NSAIDs\n* The administration of NSAIDs within 7 days\n* Not suitable for NSAIDs administration (gastrointestinal hemorrhage within 4 weeks, renal dysfunction \\[Cr \\>1.4mg\u002Fdl=120umol\u002Fl\\]; presence of coagulopathy before the procedure)\n* Acute pancreatitis within 7 days before ERCP or acute pancreatitis with obvious Pancreatic edema and peripancreatic fluid collections\n* Hemodynamical instability\n* Pregnancy or lactation\n* Unable to give informed consent","90 Years",{"count":58,"type":20},4050,"INTERVENTIONAL",[61],"NA","Pancreatitis is the most common and serious complication following post-endoscopic retrograde cholangiopancreatography (ERCP) and is associated with occasional mortality, extended hospital stays, and increased healthcare expenses. Preprocedural administration of rectal non-steroidal anti-inflammatory drugs (NSAIDs) was demonstrated to be an effective and convenient strategy for post-ERCP pancreatitis (PEP). Furthermore, several meta-analyses found that only 100mg indomethacin and diclofenac could effectively reduce PEP. Therefore, updated international clinical practice guidelines uniformly recommended administration of 100mg indomethacin or diclofenac in patients without contradictions. However, it was unclear which one of the two drug is more superior.\n\nA recent meta-analysis suggested 100mg rectal diclofenac was more efficacious than same-dose rectal indomethacin in PEP prevention (relative risk (RR) 0·59, 95% confidence intervals (CI) 0·40-0·89). Based on the results, we conducted a multicenter, double-blind, control trial to investigate whether 100mg diclofenac is superior than same-dose indomethacin. This trial planned to enroll 3612 patients in total. However, in the first interim analysis, PEP occurred in 53 patients (8.8%) of 600 patients allocated to diclofenac group and 37 patients (6.1%) of 604 patients allocated to indomethacin group (relative risk (RR) 1.44; 95% confidence interval (CI) 0.96-2.16, p=0.074). Thus, the trial was stopped according to the futility rule of conditional power. However, it was worth noticing that PEP tended to be higher in diclofenac group than that in indomethacin group. A sample size of 1204 was under power to draw the conclusion of significantly lower PEP rate in indomethacin group and thus a new trial with larger sample size of sufficient power is predicted to prove the superiority of indomethacin over diclofenac. Here we conducted a multicenter, randomized, double-blind trial to investigate whether 100mg indomethacin is superior to 100mg diclofenac in preventing PEP.",[26,64,65,66,67],"Pancreatitis","Non-steroidal Anti-inflammatory (NSAID)","Indomethacin","Diclofenac","RECRUITING","2026-06-12",{"date":71,"type":40},"2026-06-15",{"date":73,"type":40},"2025-06-01",{"date":75,"type":20},"2026-12-31",{"name":77,"class":47},"Air Force Military Medical University, China",20,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":48},"100455488","iv-fluids-and-post-ercp-pancreatitis-100455488","NCT05211206","IV Fluids and Post-ERCP Pancreatitis","Association Between Peri-procedural Intravenous Hydration and Post- Endoscopic Retrograde Cholangiopancreatography Pancreatitis","Inclusion Criteria:\n\n* Subject referred for ERCP, regardless of indication;\n* Subject age 18 years or older;\n* Subject able to give informed consent to involvement be included.\n\nExclusion Criteria:\n\n* Subject has a standard contraindication to ERCP;\n* Subject or surrogate unable or unwilling to provide informed consent;\n* Subject age \\\u003C 18 years.",{"count":87,"type":20},13000,"Aggressive intravenous hydration has been shown in randomized trials to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), though studied regimens are often impractical. To date, no studies have prospectively assessed short-term (60-90 minute) aggressive hydration regimens that are feasible for outpatients undergoing ERCP and subsequent discharge. Furthermore, little is known with regard to fluid type, volume, and timing with respect to ERCP. In this study, we will aim to assess whether the amount of peri-procedural intravenous fluid administered around the time of ERCP is associated with the risk of PEP (the primary outcome).",[26],"2026-04-28",{"date":92,"type":40},"2026-04-29",{"date":94,"type":40},"2022-01-10",{"date":96,"type":20},"2027-06-30",{"name":98,"class":47},"University of Calgary",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":26,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":59,"phases":108,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100636275","determinants-of-technical-success-and-safety-in-therapeutic-ercp-for-obstructive-jaundice-100636275","NCT07563569","Determinants of Technical Success and Safety in Therapeutic ERCP for Obstructive Jaundice","Determinants of Technical Success and Safety in Therapeutic ERCP for Obstructive Jaundice: A Prospective Comparative Study.","Inclusion Criteria:\n\n* Adult patients above 18 years old.\n* Patient with obstructive jaundice as an indication for therapeutic ERCP.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Patients below 18 years old.\n* Indications for ERCP other than obstructive jaundice.\n* with coagulopathy not corrected prior to procedure.\n* severe active cardiopulmonary comorbidities.\n* Previous altered upper GIT anatomy (e.g gastric by-pass).\n* Pregnancy",{"count":107,"type":20},100,[61],"compare the impact of type of anesthesia on ERCP including technical success, rate of complications, peri procedural safety, patient and endoscopist satisfaction in adult patients with obstructive jaundice",[111,26,112,113],"Obstructive Jaundice","Anesthesia Complication","Anesthesia Effectiveness",[26],"2026-04-25",{"date":117,"type":40},"2026-05-04",{"date":119,"type":20},"2026-05-20",{"date":121,"type":20},"2027-05-20",{"name":123,"class":47},"Sohag University",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":59,"phases":135,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100597252","prevention-of-desaturations-using-positive-airway-pressure-or-capnometry-during-ercp-100597252","NCT07056075","Prevention of Desaturations Using Positive Airway Pressure or Capnometry During ERCP","A Randomized, Controlled, Unblinded Trial Evaluating the Impact of Positive Airway Pressure and Capnometry Compared to Standard Management on the Rate of Desaturations During Nurse-administered Sedation ERCP","PrePAP-ERCP","Inclusion Criteria:\n\n* undergoing an interventional (intent) ERCP procedure\n* 18-99 years\n* Male or female\n* Nurse-administered sedation\n\nExclusion Criteria:\n\n* History of allergic reaction to Propofol\n* Tracheostomy\n* Procedure requiring intubation, general anesthesia, or anesthesiologist backup (acute exacerbation of obstructive lung disease, acute congestive heart failure, supra-glottic or sub-glottic tumor, septic shock, e.g.) according to the endoscopist in charge\n* Pregnant patients","99 Years",{"count":134,"type":20},288,[61],"Although sedation during endoscopy is sufficiently safe, desaturations are among the most common side effects of endoscopic retrograde cholangiopancreatography (ERCP) procedures, occurring in approximately 20-30% of cases. Sedation during endoscopy increases the complication rate, and a significant proportion of severe and serious side effects are respiratory\u002Fairway-related. However, most patients require sedation to complete the procedure and achieve adequate outcomes during therapeutic ERCP. Therefore, improved measures to increase ERCP safety are needed. Since the demand for anesthesia in many centers already (far) exceeds current capacities, performing additional ERCPs under general anesthesia is not an option. Innovative ways to improve cardiorespiratory monitoring or respiratory management during ERCP could offer a solution without significantly increasing costs. Fortunately, dedicated devices for respiratory management and\u002For monitoring during endoscopy already exist, but their impact on improving patient safety has not yet been well studied. Therefore, the aim of this prospective, randomized, open-label, non-interventional study is to investigate the effects of non-invasive airway management and respiratory monitoring devices on desaturation rate during endoscopic retrograde cholangiopancreatography.\n\nFor this purpose, 288 adult patients (male and female, 18+ years) undergoing ERCP for medical reasons will be enrolled and randomized to one of three groups: (i) airway management using positive airway pressure (PAP group), (ii) additional monitoring using capnography (capnography group), and (iii) a control group with standard monitoring\u002Ftreatment (i.e., 2 L O2\u002Fmin via nasal cannula) (control group). Patients are monitored during the ERCP procedure according to medical standards (non-invasive blood oxygen saturation measurement = SpO2, regular non-invasive blood pressure measurement, pulse), and all desaturation events (defined as an SpO2 \\\u003C85% for any duration according to guidelines) are recorded and treated according to guideline recommendations (the studies do not specify any measures for the (non-)treatment of desaturations). After the procedure, patients are followed (passively) for 30 days (review of medical records) to record late complications. The main outcome parameter is the comparison of the desaturation rate in the PAP versus the control group.",[138,139,26],"Desaturation","Hypoxemia",[26,141,142,143],"Sedation-related adverse events","desaturation","trial","2026-03-21",{"date":146,"type":40},"2026-03-24",{"date":148,"type":40},"2025-07-07",{"date":150,"type":20},"2026-12-30",{"name":152,"class":47},"Karl Landsteiner University of Health Sciences",2,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":48},"100611734","post-ercp-pancreatitis---prophylactic-measures-implementation-study-pep-promis-100611734","NCT07244432","Post-ERCP Pancreatitis - Prophylactic Measures Implementation Study (PEP-PROMIS)","Post-ERCP Pancreatitis- Prophylactic Measures Implementation Study","PEP-PROMIS","Inclusion Criteria:\n\n* ERCP in a patient with a native papilla (first ERCP) or repeat ERCP in a patient with previous failed cannulation attempt.\n* Age at least 18 years at the time of ERCP.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Previous papillotomy, papilla dilation, or sphincteroplasty.\n* Rendez-vous cannulation technique.\n* ERCP not performed due to insufficient patient cooperation.\n* ERCP terminated before cannulation due to sedation\u002Fanesthesia-related complications.\n* Failure to reach the Vater's or minor papilla (e.g. duodenal stenosis).\n* Acute biliary pancreatitis.\n* Altered anatomy that prevents reaching the papilla with a standard duodenoscope (e.g. Roux-en-Y).",{"count":163,"type":20},1000,"This is a prospective, observational (non-interventional), multicenter study that will look at how often inflammation of the pancreas (called post-ERCP pancreatitis, or PEP) occurs after an endoscopic procedure known as ERCP. The study will take place in several hospitals in Slovakia and Czechia and will include all patients who have this procedure during the study period.\n\nERCP is a common procedure used to treat problems in the bile ducts and pancreas. Although generally safe, it sometimes leads to PEP, which is the most frequent and potentially serious complication. Monitoring the rate of PEP helps doctors evaluate the overall quality of ERCP procedures, since patient safety is an important part of quality care.\n\nThe study will also look at how well hospitals follow current prevention guidelines from two major professional organizations-the European Society of Gastrointestinal Endoscopy (ESGE) and the American Society for Gastrointestinal Endoscopy (ASGE)-and how these prevention methods affect the risk of PEP. This information will help identify how closely real-world practice follows recommended preventive measures and provide new data about PEP rates in the region.",[166,26,167],"Pancreatitis, Acute","Prophylaxis","2026-02-18",{"date":170,"type":40},"2026-02-20",{"date":172,"type":40},"2025-12-01",{"date":174,"type":20},"2026-05-31",{"name":176,"class":47},"Branislav Kuncak",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":185,"maxAge":56,"enrollmentInfo":186,"targetDuration":4,"studyType":59,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100621896","efficacy-and-safety-of-anricofen-combined-with-ciprofol-for-deep-sedation-in-elderly-patients-undergoing-ercp-100621896","NCT07376577","Efficacy and Safety of Anricofen Combined With Ciprofol for Deep Sedation in Elderly Patients Undergoing ERCP","A Randomized Controlled Trial on the Efficacy and Safety of Anricofen Combined With Ciprofol for Deep Sedation in Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography","Anricofen Cipr","Inclusion Criteria:\n\n\\-\n\nInclusion Criteria:\n\n1. Age 60-90 years.\n2. American Society of Anesthesiologists (ASA) physical status II or III.\n3. Scheduled for elective endoscopic retrograde cholangiopancreatography (ERCP).\n4. Body mass index (BMI) between 18 and 30 kg\u002Fm².\n5. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Severe neurological disorders (acute stroke, uncontrolled seizures, epilepsy).\n2. Psychiatric disorders or cognitive impairment (Mini-Mental State Examination score \\\u003C24).\n3. Uncontrolled hypertension (preoperative blood pressure ≥180\u002F110 mmHg) or hypotension (\\\u003C90\u002F60 mmHg).\n4. Severe cardiac disease: sinus bradycardia, sick sinus syndrome, unstable angina, or myocardial infarction within the past 3 months.\n5. Severe hepatic or renal dysfunction.\n6. Difficult airway or severe respiratory disease.\n7. Achalasia.\n8. Known allergy to anricofen, sufentanil, ciprofol, or other study medications.\n9. Use of opioid analgesics or sedatives within 7 days prior to surgery.\n10. Preoperative pulse oxygen saturation (SpO₂) \\\u003C90% on room air.\n11. Pregnancy or lactation.\n12. Participation in any other drug clinical trial within the past 3 months.\n13. Refusal to participate in the study.\n\nExclusion Criteria:\n\n\\-","60 Years",{"count":187,"type":20},141,[61],"Background: Endoscopic retrograde cholangiopancreatography (ERCP) is a key technique for treating pancreatobiliary diseases in the elderly. However, traditional sedative and analgesic regimens (e.g., sufentanil combined with propofol) are associated with a high incidence of respiratory depression, postoperative nausea and vomiting (PONV), and delayed recovery in elderly patients. Anricofen is a novel peripherally selective κ-opioid receptor agonist that provides analgesia with minimal central respiratory depression. Ciprofol is a new sedative agent characterized by rapid onset and quick recovery. The combination of these two drugs may offer a safer sedation and analgesia regimen for elderly patients undergoing ERCP.\n\nObjective: To evaluate the efficacy and safety of anricofen combined with ciprofol for deep sedation in elderly patients undergoing ERCP, compared with the traditional regimen (sufentanil combined with ciprofol).\n\nMethods: This is a single-center, randomized, double-blind, controlled trial. A total of 141 elderly patients aged 60-90 years with ASA physical status II-III scheduled for elective ERCP will be enrolled and randomly assigned in a 1:1:1 ratio to three groups: Anricofen 0.3 μg\u002Fkg + Ciprofol 1.0 mg\u002Fkg, Anricofen 0.5 μg\u002Fkg + Ciprofol 1.0 mg\u002Fkg, or Sufentanil 0.1 μg\u002Fkg + Ciprofol 1.0 mg\u002Fkg. The primary efficacy endpoint is the intraoperative pain control success rate (proportion of time with Behavioral Pain Scale \\[BPS\\] score ≤3 ≥90%). The primary safety endpoint is the incidence of respiratory depression (respiratory rate \\\u003C10 breaths\u002Fmin or SpO₂ \\\u003C90% requiring intervention). Secondary outcomes include sedation depth, body movement episodes, recovery time, PONV incidence, and others.\n\nSignificance: This study aims to provide a sedation and analgesia regimen with lower risk of respiratory depression and faster recovery for elderly patients undergoing ERCP.",[191,192,26,193],"Anesthesia","Sedation","Ciprofol","2026-01-26",{"date":196,"type":40},"2026-01-29",{"date":198,"type":20},"2026-01-01",{"date":200,"type":20},"2028-05-01",{"name":202,"class":47},"The First Affiliated Hospital of Xinxiang Medical College",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":59,"phases":213,"briefSummary":214,"conditions":215,"keywords":220,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":231,"leadSponsor":233,"locationsCount":48},"100619572","spontaneous-dislocation-and-adverse-events-of-a-prophylactic-pancreatic-stent-100619572","NCT07346365","Spontaneous Dislocation and Adverse Events of a Prophylactic Pancreatic Stent","Spontaneous Dislocation and Adverse Events of a Prophylactic Pancreatic Stent: a Prospective, Randomised, Multicenter Study (SAFE PANCREAS)","SAFE PANCREAS","Inclusion Criteria:\n\n* prophylactic pancreatic stent (5Fr 4cm length)\n* informed consent\n\nExclusion Criteria:\n\n* necrotising post-ercp-pancreatitis\n* pregnancy\u002Fbreastfeeding\n* Billroth II",{"count":212,"type":20},358,[61],"A multicenter, prospective, controlled randomized study to investigate the optimal duration of protective pancreatic stents after endoscopic retrograde cholangiopancreatography (ERCP).\n\nThe primary endpoint is the complication rate that can be clinically attributed to the remaining pancreatic prosthesis or its removal in the study groups. Secondary endpoints are spontaneous removal of the pancreatic stent, length of hospital stay, rate of follow-up examinations per group, influencing factors, and a possible exploratory analysis.",[216,26,217,218,219],"Stent Dislodgement","Pancreas Stent","Post-ERCP Pancreatitis","Prophylactic Pancreatic Stent",[221,222,223,224,225,226],"ercp","prophylactic pancreatic stent","post-ercp-pancreatitis","pancreatic stent","post-ercp pancreatitis","PEP","2026-01-14",{"date":229,"type":40},"2026-01-16",{"date":198,"type":20},{"date":232,"type":20},"2032-06",{"name":234,"class":47},"Johann Wolfgang Goethe University Hospital",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":59,"phases":245,"briefSummary":246,"conditions":247,"keywords":252,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100618298","pre-cut-versus-intentional-double-guidewire-for-ercp-cannulation-prospective-randomized-controlled-trial-100618298","NCT07329803","Pre-cut Versus Intentional Double Guidewire for ERCP Cannulation: Prospective, Randomized Controlled Trial","PRIDE","Inclusion Criteria:\n\n\\- Age \\> 18 years.\n\n* Valid indication for ERCP (benign or malignant obstruction).\n* Native papilla (no prior sphincterotomy).\n* Difficult Biliary Cannulation (DBC) defined by ESGE \"5-5-2\" criteria:\n* \\> 5 minutes of cannulation attempts.\n* \\> 5 contacts with the papilla.\n* \\> 1 inadvertent pancreatic duct cannulation.\n\nExclusion Criteria:\n\n* Ampullary mass or tumor preventing standard cannulation view.\n\n  * Surgically altered anatomy (e.g., Billroth II, Roux-en-Y).\n  * Uncorrectable coagulopathy (INR \\> 1.5 or Platelets \\\u003C 50,000).\n  * Acute pancreatitis present prior to ERCP.","75 Years",{"count":244,"type":20},840,[61],"Endoscopic retrograde cholangiopancreatography (ERCP) is an indispensable therapeutic procedure in the management of a wide spectrum of pancreaticobiliary disorders, including choledocholithiasis, benign and malignant biliary strictures, pancreatic ductal obstructions, and postoperative bile leaks. The procedure has revolutionized the management of these conditions, often obviating the need for surgery.Precut papillotomy and Double Guidewire Technique (DGT) are both salvage techniques used in ERCP when standard biliary cannulation fails.\n\nPrecut (Needle-Knife Precut): An endoscopic incision made into the papilla to gain access to the bile duct when conventional methods fail.\n\nIntentional Double Guidewire Technique (DGT): A technique where a guidewire is intentionally placed into the pancreatic duct to act as a \"guide\" or anchor, straightening the biliary axis and allowing a second guidewire to be inserted into the bile duct.",[26,248,249,250,251],"Choledocholithiasis","Biliary Drainage","Biliary Strictures Caused by Malignant Neoplasms","Biliary Stricture",[253,254,255,256],"Selective CBD cannulation","Post ERCP Pancreatitis","Precut Sphincterotomy","Double Guidewire Technique","2026-01-09",{"date":259,"type":40},"2026-01-12",{"date":261,"type":20},"2026-01-25",{"date":263,"type":20},"2027-02-28",{"name":265,"class":47},"Asian Institute of Gastroenterology, India",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":242,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":4},"100618297","indian-national-study-to-assess-incidence-and-severity-of-post-ercp-pancreatitis-after-following-sop-100618297","NCT07329790","Indian National Study to Assess Incidence and Severity of Post-ERCP Pancreatitis After Following SOP","INSPIRE","Inclusion Criteria:\n\nConsecutive ERCPs during the enrollment window.\n\n* Males and females between 18 and 75 years of age who ca comprehend instructions, follow study procedures, willing to sign an informed consent form and have a clinical indication to undergo a ERCP.\n* Patients undergoing ERCP for therapeutic indications\n* Patients with intact papilla\n\nExclusion Criteria:\n\n* patient undergoing ERCP for diagnostic indications\n* Acute pancreatitis\n* Previous sphincterotomy\n* Altered anatomy, defined as anatomical variations in which bile and\u002For pancreatic secretion donot enter the duodenum by way of the ampulla of Vater\n* Pregnancy\n* Signs of Congestive heart failure, such as pitting edema or a NYHA classification greater than class II heart failure.\n* Respiratory insufficiency (pO2 \\\u003C 60 mmHg or saturation \\\u003C 90% despite FiO2 of 30% or requiring mechanical ventilation).\n* Severe liver disease (cirrhosis and ascites)\n* Contraindication for rectal indomethacin",{"count":274,"type":20},2366,"Endoscopic retrograde cholangiopancreatography (ERCP) is an indispensable therapeutic procedure in the management of a wide spectrum of pancreaticobiliary disorders, including choledocholithiasis, benign and malignant biliary strictures, pancreatic ductal obstructions, and postoperative bile leaks. The procedure has revolutionized the management of these conditions, often obviating the need for surgery. However, despite its therapeutic efficacy, ERCP carries a significant risk of procedure-related adverse events, of which post-ERCP pancreatitis (PEP) is the most common and clinically important complication.\n\nThe reported incidence of PEP in prospective multicenter studies ranges from 7 % to 10 % in unselected populations, and may increase to 15 % or higher in high-risk subsets such as patients with difficult cannulation, sphincter of Oddi dysfunction, or a prior history of pancreatitis or PEP. Although the majority of cases are mild and self-limited, a small but important proportion (approximately 10-15 %) progress to moderate or severe disease, resulting in prolonged hospitalization, increased cost, and occasionally mortality.\n\nOver the past two decades, extensive research has improved our understanding of PEP pathogenesis and risk stratification. Several patient-related (younger age, female sex, prior PEP or pancreatitis, sphincter of Oddi dysfunction, asymptomatic choledocholithiasis) and procedure-related (difficult cannulation, pancreatic duct contrast injection or guidewire passage, pancreatic sphincterotomy, endoscopic papillary balloon dilation) predictors have been identified.",[26],{"date":259,"type":40},{"date":279,"type":20},"2026-01-10",{"date":281,"type":20},"2026-07-30",{"name":265,"class":47},{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":59,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":48},"100603003","early-vs-late-laparoscopic-cholecystectomy-after-common-bile-duct-stones-clearance-through-ercp-100603003","NCT07130864","Early vs Late Laparoscopic Cholecystectomy After Common Bile Duct Stones Clearance Through Ercp.","Early Vs Late Laparoscopic Cholecystectomy After Ercp For Choledocholithiasis, A Randomised Control Trial.","Inclusion criteria :\n\n.All patients undergoing laparoscopic cholecystectomy who had concomitant choledocholithiasis for which ercp is done.\n\nexclusion criteria:\n\n.Non consenting indviduals",{"count":291,"type":20},136,[61],"There is controversy about timing of cholecystectomy after the common bile duct is cleared of stones. our study aims to compare the results of early vs late cholecystectomy.",[295,248,26,296],"Laparoscopic Cholecystectomy","Bile Duct Injury","2025-08-18",{"date":299,"type":40},"2025-08-19",{"date":301,"type":40},"2025-05-23",{"date":303,"type":20},"2025-12-31",{"name":305,"class":47},"Khyber Teaching Hospital",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":313,"maxAge":17,"enrollmentInfo":314,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":316,"conditions":317,"keywords":321,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":4},"100585317","management-of-pediatric-pancreatic-calculi-at-a-single-center-a-retrospective-cohort-study-100585317","NCT06900790","Management of Pediatric Pancreatic Calculi At a Single Center: a Retrospective Cohort Study","A Single-Center Retrospective Cohort Study Evaluating the Management and Outcomes of Pediatric Pancreatic Duct Stones Using Endoscopic and Surgical Techniques","Inclusion Criteria:\n\n* Patients aged 0 to 18 years\n* Diagnosed with pancreatic duct stones by imaging (e.g., ultrasound, CT, MRCP)\n* Treated and followed at pediatric surgery, west china hospital, between 2014 and 2025\n* Complete clinical data available for review\n\nExclusion Criteria:\n\n* Pancreatic duct stones secondary to previous pancreatic or biliary surgery\n* Concurrent severe systemic diseases (e.g., advanced cardiac, renal, or hepatic disease)\n* Incomplete or missing key clinical records","2 Months",{"count":315,"type":20},60,"The goal of this observational study is to evaluate the long-term effects of ERCP and surgery in pediatric patients with pancreatic duct stones. The main objective is to determine the optimal treatment choice(ERCP or surgery) for children with pancreatic duct stones and identify the appropriate timing for surgery in patients who have undergone multiple ERCP procedures, in order to avoid adverse outcomes caused by repeated trauma to the duodenal papilla.\n\nLast updated on January 24, 2025.",[318,26,319,320],"Pancreatic Duct Stenting","Surgery in Early Childhood","Pediatric Surgery",[322,26,323],"pancreatic duct stones","Frey surgery","2025-03-23",{"date":326,"type":40},"2025-03-28",{"date":328,"type":20},"2025-04-23",{"date":330,"type":20},"2025-12-23",{"name":332,"class":47},"Yifan Deng"]